Abstract
Chemokine receptors belong to the transmembrane G protein coupled receptor (GPCR) family. Although a major physiological role of chemokine receptors is for host defense by recruitment of lymphocytes to inflammatory sites, they are now found to be involved in more processes such as virus infection, tumor genesis and metastasis, and embryologic development. In this review, we show an overall picture of chemokine receptors in structure, signal transduction and modulation, physiological and pathological roles, and applying chemokine receptors for drug discovery.
Keywords: chemokine receptor, g protein coupled receptor, signal transduction, ligand
Current Pharmaceutical Design
Title: An Overall Picture of Chemokine Receptors: Basic Research and Drug Development
Volume: 10 Issue: 9
Author(s): Li Chen, Gang Pei and Wenbo Zhang
Affiliation:
Keywords: chemokine receptor, g protein coupled receptor, signal transduction, ligand
Abstract: Chemokine receptors belong to the transmembrane G protein coupled receptor (GPCR) family. Although a major physiological role of chemokine receptors is for host defense by recruitment of lymphocytes to inflammatory sites, they are now found to be involved in more processes such as virus infection, tumor genesis and metastasis, and embryologic development. In this review, we show an overall picture of chemokine receptors in structure, signal transduction and modulation, physiological and pathological roles, and applying chemokine receptors for drug discovery.
Export Options
About this article
Cite this article as:
Chen Li, Pei Gang and Zhang Wenbo, An Overall Picture of Chemokine Receptors: Basic Research and Drug Development, Current Pharmaceutical Design 2004; 10 (9) . https://dx.doi.org/10.2174/1381612043452749
DOI https://dx.doi.org/10.2174/1381612043452749 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
MDM2 and Human Malignancies: Expression, Clinical Pathology, Prognostic Markers, and Implications for Chemotherapy
Current Cancer Drug Targets Antiangiogenic Therapy
Current Pharmaceutical Design Targeting Heme for the Identification of Cytotoxic Agents
Anti-Cancer Agents in Medicinal Chemistry Quantum Dot-Based Nanoprobes for In Vivo Targeted Imaging
Current Molecular Medicine Of Man in Mouse: Modelling Human Cancer Genotype-Phenotype Correlations in Mice
Current Genomics Positron Emitting Tracers in Pre-Clinical Drug Development
Current Radiopharmaceuticals A Review of Pharmacological and Phytochemical Studies on Convolvulaceae Species <i>Rivea</i> and <i>Ipomea</i>
Current Traditional Medicine Inhibition of Polo-Like Kinase 1 by BI2536 Reverses the Multidrug Resistance of Human Hepatoma Cells In Vitro and In Vivo
Anti-Cancer Agents in Medicinal Chemistry Nutlin-3, A p53-Mdm2 Antagonist for Nasopharyngeal Carcinoma Treatment
Mini-Reviews in Medicinal Chemistry Azathioprine in Multiple Sclerosis
Mini-Reviews in Medicinal Chemistry Src Tyrosine Kinase Inhibition Suppresses Lymphangiogenesis In Vitro and In Vivo
Current Cancer Drug Targets Multifunctional Dendritic Drug Delivery Systems: Design, Synthesis, Controlled and Triggered Release
Current Topics in Medicinal Chemistry Targeting Hypoxia for Sensitization of Tumors to Radio- and Chemotherapy
Current Cancer Drug Targets Naphthyridines with Antiviral Activity - A Review
Medicinal Chemistry Eph Receptor Tyrosine Kinases in Tumor and Tumor Microenvironment
Current Pharmaceutical Design Heart Failure in Sub-Saharan Africa
Current Cardiology Reviews Inhibiting the “Undruggable” RAS/Farnesyltransferase (FTase) Cancer Target by Manumycin-related Natural Products
Current Medicinal Chemistry Dual Inhibitors of PI3K/mTOR or mTOR-Selective Inhibitors: Which Way Shall We Go?
Current Medicinal Chemistry Targeting the Programmed Cell Death-1 Pathway in Genitourinary Tumors: Current Progress and Future Perspectives
Current Drug Metabolism Folate-Linked Lipid-Based Nanoparticle for Targeted Gene Delivery
Current Drug Delivery